100% Recovery-GoldenBiotech Announces Topline Results from Unblinded COVID-19 Trial for Oral New Drug Antroquinonol in Hospitalized Mild, Moderate and Severe Patients
TAIPEI, Jan. 7, 2022 /PRNewswire/ -- Golden Biotechnology Corp.(TPEx:4132) ("GoldenBiotech", GBC), a leading Taiwanese biopharmaceutical company, announces that its Phase 2 COVID-19 trial for oral new drug Antroquinonol (HOCENA®) has achieved 100% recovery results of its primary outcome measure i...
COVID-19 Scoop: Epoch-Making GoldenBiotech's Oral COVID-19 New Drug Trial Got Green Light from the FDA to Extend Recruiting Severe COVID-19 Patients
TAIPEI, Sept.16, 2021 /PRNewswire/ -- Golden Biotechnology Corp.(TPEx:4132) ("GoldenBiotech", GBC), a leading Taiwanese biopharmaceutical company, announces that its oral investigational new drug Antroquinonol (HOCENA®) has made headway withCOVID-19 treatment development in more broaden clinical ...
Covid-19 Drug Duo Achievements: GoldenBiotech's New Drug Antroquinonol (HOCENA) Trial Receives Positive Response from DMC Review and Licenses for 4 Countries
TAIPEI, Feb.4, 2021 /PRNewswire/ -- Golden Biotechnology Corp.(TPEx:4132)("GoldenBiotech"), a leading Taiwanese biopharmaceutical company, announced that it has made two achievements for its Covid-19 new drug candidate Antroquinonol® (HOCENA®): receiving positive response after DMC review in Pha...
Covid-19 Drug Duo Achievements: GoldenBiotech's New Drug Antroquinonol (HOCENA) Trial Receives Positive Response from DMC Review and Licenses for 4 Countries
TAIPEI, Feb. 4, 2021 /PRNewswire/ -- Golden Biotechnology Corp.(TPEx:4132)("GoldenBiotech"), a leading Taiwanese biopharmaceutical company, announced that it has made two achievements for its Covid-19 new drug candidate Antroquinonol® (HOCENA®): receiving positive response after DMC review in Ph...
Breakthrough in AML Treatment: GoldenBiotech Reports New Drug Trial of Antroquinonol -Outperforms Listing Drugs in Relapsed Acute Myeloid Leukemia
TAIPEI, Nov. 26, 2020 /PRNewswire/ -- Golden Biotechnology Corp.(GoldenBiotech, 4132.TWO), a leading Taiwanese biopharmaceutical company, announces that its new drug Antroquinonol (HOCENA®) outperforms the other listing drugs for the treatment of relapsed AML (acute myeloid leukemia) patients in ...
Anti-viral and Anti-Inflammatory Response: GoldenBiotech's Antroquinonol Receives FDA Approval on COVID-19 Phase 2 Trial in USA
TAIPEI, July 1, 2020 /PRNewswire/ -- Golden Biotechnology Corp. (GoldenBiotech, 4132.TWO), a leading Taiwanese biopharmaceutical company, announced that the FDA approved its investigational new drug (IND) application for a Phase II clinical trial of Antroquinonol (Hocena®) on COVID-19 patients in...
